RBC Capital raises Dow stock price target on strong earnings outlook

RBC Capital raised its price target on Dow Inc. to $51 from $47 and kept an Outperform rating, citing higher earnings estimates and improved EBITDA visibility to more than $6 billion for 2026. The firm lifted 2026 EBITDA estimates to $6.0 billion from $4.7 billion and 2027 estimates to $6.5 billion from $5.3 billion, supported by margin gains and cost savings. Dow also recently beat Q1 2026 EPS and revenue expectations, reinforcing the positive outlook.

Analysis

The key implication is not just higher earnings, but a reset in the market’s perception of Dow’s cyclicality. If management can sustain a mid-cycle EBITDA anchor near the new estimate, the equity should trade less like a peak-commodity call option and more like a cash-generative balance sheet story, which matters because multiples usually expand before the numbers fully land. The cleaner read-through is to other North American commodity chemical names: this improves the probability that the entire group can re-rate if spreads stay firm into the summer maintenance window, but it also raises the bar for any company still lagging on cost-out or operating discipline.

The second-order effect is on feedstock-sensitive competitors and downstream buyers. A polyethylene margin tailwind that is broad-based tends to compress differentiation across producers, so the “beta” winners are likely the lowest-cost, best-capacity-utilization operators, while higher-cost or more levered names become relative underperformers if the cycle rolls over. For end-markets, better chemicals profitability often precedes some repricing pressure in packaging, consumer durables, and autos as producers try to hold margin, so the squeeze may show up downstream with a lag rather than immediately in the chemical stocks themselves.

The main risk is that this is an earnings revisions story built on a narrow spread snapshot and execution assumptions that can reverse quickly over 1–2 quarters. If polyethylene margins mean-revert or turnarounds slip, the multiple will contract faster than consensus can cut numbers, especially after a strong rerating run. The contrarian view is that the market may already be pricing an orderly recovery, while the real upside would require a more durable mid-cycle confirmation in 2026; absent that, the stock can still work operationally but may not justify chasing after a large rally.

From a positioning perspective, the opportunity is better expressed as relative value than outright momentum: the setup favors owning the best-operating name versus laggards with weaker self-help or less visible 2026 EBITDA leverage. The valuation signal also argues for using options to define risk, because the upside is increasingly about multiple sustainability rather than just estimate revisions.

Key Decisions for Investors

• Long DOW vs. short a weaker North American chemicals peer basket for 3-6 months; best expression if spreads stay constructive and the market continues to reward earnings visibility.
• Buy DOW call spreads expiring in 3-6 months to capture further multiple expansion while limiting downside if polyethylene margins normalize faster than expected.
• Trim or avoid chasing outright long exposure in the broader chemicals group after the recent rerating; the risk/reward is now more favorable in relative-value than momentum trades.
• If holding downstream industrial or consumer packaging names, hedge a portion of exposure for 1-2 quarters as improved chemical pricing power can pressure input-sensitive margins with a lag.